•  
  •  
 

Subject Area

Dermatology

Article Type

Original Study

Abstract

Objective This study aimed to investigate the relation between endoglin as an endothelial marker in smoker and nonsmoker patients with erectile dysfunction (ED). Background ED is a benign disorder, but it can have a significant effect on the quality of life of the patients, partners, and families. Patients and methods A prospective randomized study was conducted on 90 men having ED and attending the Andrology Clinic in Menoufia University Hospital during the period from October 2020 to March 2021. Results Regarding clinical data (P < 0.05), 33.3% of nonsmokers with ED had diabetes, whereas 36.7% of smokers with ED had diabetes and hypertension and 83.3% of control group had no commodities (P = 0.001). All smokers with ED and nonsmokers with ED had metabolic syndrome. BMI and waist circumference were significantly higher in nonsmokers with ED group than nonsmokers with ED and control groups. There was a statistically significant difference between smokers with ED and nonsmokers with ED regarding mean serum endoglin level, as it was higher in smokers than nonsmokers (17.6 ± 0.97 vs. 14.0 ± 0.17) (P < 0.001). Moreover, serum endoglin was higher in smokers with ED and in nonsmokers with ED than in the control group (9.23 ± 0.69) (P < 0.001). Conclusions Endoglin can be considered as the endothelial dysfunction marker in male smokers with ED.

Download

Share

COinS